Research Article

Administration of N-Acetylcysteine to Regress the Fibrogenic and Proinflammatory Effects of Oxidative Stress in Hypertrophic Ligamentum Flavum Cells

Yu-Chia Hsu,1 Hao-Chun Chuang,1 Kun-Ling Tsai,2 Ting-Yuan Tu,3 Yan-Yje Shyong,4 Cheng-Hsiang Kuo,5 Yuan-Fu Liu,1 Shu-Shien Shih,1 and Cheng-Li Lin1

1Department of Orthopaedic Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3Department of Biomedical Engineering, National Cheng Kung University, Tainan, Taiwan
4Department of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan 70101, Taiwan
5Department of Biochemistry and Molecular Biology, National Cheng Kung University, Tainan, Taiwan

Correspondence should be addressed to Cheng-Li Lin; jengli94@gmail.com

Received 6 July 2022; Revised 22 July 2022; Accepted 20 September 2022; Published 26 October 2022

Academic Editor: Alessandra Durazzo

Copyright © 2022 Yu-Chia Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ligamentum flavum hypertrophy (LFH) is a major cause of lumbar spinal stenosis (LSS). In hypertrophic ligamentum flavum (LF) cells, oxidative stress activates intracellular signaling and induces the expression of inflammatory and fibrotic markers. This study explored whether healthy and hypertrophic LF cells respond differently to oxidative stress, via examining the levels of phosphorylated p38 (p-p38), inducible nitric oxide synthase (iNOS), and α-smooth muscle actin (α-SMA). Furthermore, the efficacy of N-acetylcysteine (NAC), an antioxidant, in reversing the fibrogenic and proinflammatory effects of oxidative stress in hypertrophic LF cells was investigated by assessing the expression levels of p-p38, p-p65, iNOS, TGF-β, α-SMA, vimentin, and collagen I under H2O2 treatment with or without NAC. Under oxidative stress, p-p38, p-p65, iNOS, TGF-β, α-SMA, vimentin, and collagen I increased significantly, and NAC administration reversed the effects of oxidative stress. These results can form the basis of a novel therapeutic treatment for LFH using antioxidants.

1. Introduction

Lumbar spinal stenosis (LSS) was first described in 1900 [1], and its symptoms include backache, numbness, or bladder disturbance [2]. It is a common disease with an estimated prevalence of 19.4% in people in their sixties [3]. Ligamentum flavum hypertrophy (LFH) is considered a major cause of LSS [4]. LFH is usually treated with oral analgesics, surgical intervention, and rehabilitation [5]. However, oral analgesics such as nonsteroidal anti-inflammatory drugs have multiple adverse effects, including gastrointestinal bleeding and kidney function impairment. Therefore, developing novel pharmacological therapies for LFH with relatively minimal side effects is imperative. Recent studies have revealed multiple pathomechanisms for LFH, including histologic changes that involve elevated collagen and diminished elastic fiber content, increased inflammatory cytokine levels (e.g., inducible nitric oxide synthase (iNOS), matrix metalloproteinase (MMP), interleukin (IL-) 6, and IL-8 levels), increased growth factor expression (e.g., transforming growth factor-
(TGF-) β and vascular endothelial growth factor expression), and focal angiogenesis [6–13]. However, despite the known etiologies, a targeted therapy for LFH has yet to be developed.

Recently, elevated oxidative stress and increased oxidative DNA damage have been observed in patients with LFH [14–16]. In 2020, one study noted increased production of reactive oxygen species (ROS) and decreased levels of endogenous antioxidants such as glutathione (GSH) and superoxide dismutase in hypertrophic ligamentum flavum (LF) cells; the study also revealed that under oxidative stress stimulation, the upregulation of intracellular signaling pathways and elevated expression levels of fibrotic and inflammatory markers were identified [17]. Oxidative stress is a major pathogenic factor in the development of LFH as well as in other diseases such as Parkinson disease (PD), acute lung injury, ischemic heart disease, chronic kidney disease, liver cirrhosis, and pelvic organ prolapse [18–26].

Considering the role of oxidative stress in disease development, studies have administered antioxidants such as N-acetylcysteine (NAC), curcumin, β-carotene, vitamins, coenzyme Q10, and folic acid for therapy and have noted diverse clinical responses depending on the disease. Moreover, antioxidants have been applied for treating diseases associated with a wide range of organs or systems, including the brain, lungs, heart, vascular system, liver, and kidneys [18, 20, 23, 27–30]. Accordingly, we conducted this study with the aim of exploring the effects of an antioxidant, namely, NAC, on LFH. Our study is the first to apply an antioxidant agent for LFH therapy. We chose NAC because of its ability to increase GSH precursors [31] and its minimal adverse effects, especially when compared with oral analgesics [32].

Because of the association between oxidative stress and LFH, NAC is proposed as a possible treatment option for LFH. In this study, we first compared the response of healthy LF cells and that of pathologically hypertrophic LF cells to oxidative stress. The inflammatory and intracellular signaling in hypertrophic LF cells was hypothesized to respond more significantly compared with their healthy counterparts. Second, we evaluated the ameliorative effects of NAC on the blockage of oxidative stress-induced inflammation and fibrosis in hypertrophic LF cells.

2. Methods

2.1. Participants and Magnetic Resonance Imaging Analysis. After excluding patients with a history of epidural or selective nerve-root blocks, malignancy, vertebral fracture, vertebral osteomyelitis, or previous spine surgery, we included 52 patients undergoing spinal surgery at a tertiary referral hospital in southern Taiwan. Patient characteristics for LFH were obtained from other studies [33, 34]. All patients underwent magnetic resonance imaging (MRI) preoperatively. The maximum thickness of the LF was measured using axial T2-weighted images acquired at the facet-joint level of the lesion (Figure 1) [35]. The radiographic analyses were performed by two senior spine surgeons independently, who were not involved in providing clinical care to the patients. The surgeons each measured the thickness of the LF twice, and the average of the four measurements was used as the final result.

We aseptically collected hypertrophic LF specimens from 28 patients with LSS (LSS group) during posterior lumbar decompression surgery. Moreover, we collected healthy LF tissue samples from 24 patients with lumbar disc herniation (LDH; LDH group) during lumbar discectomy surgery. The LF at the diseased lumbar level was yielded en bloc, and the epidural fat and bone-ligament junction were accurately removed. Fifteen specimens from the LDH group and 40 specimens from the LSS group were used for LF cell isolation.

The study was conducted according to the Declaration of Helsinki and approved by the Institutional Review Board of National Cheng Kung University Hospital (A-ER-108-541, A-ER-110-001). The protocol in the study was reviewed by the Protection of Human Subjects Committee. All 52 patients recruited provided written informed consent.

2.2. Human LF Cell Characterization. In this study, human ligamentum flavum cells were characterized by high levels of alkaline phosphatase activity, production of a matrix rich in type I and III collagen, expression of fibronectin, and a spindle or polygonal morphology, as described by Specchia et al. [36, 37]. We performed immunofluorescence analyses of collagen type I, collagen type III, and fibronectin, which were visualized using FITC (green) and the nuclei by DAPI (blue). Also, the alkaline phosphatase activity was assessed by exposing fixed cultures for 30 minutes to a solution containing BCIP-NBT (Sigma). Cells cultured in the current study expressed collagen type I, collagen type III, and fibronectin and were positive for alkaline phosphatase activity. The morphology of ligamentum flavum cells was primarily spindle-shaped and polygonal as previous studies (Figure 2).

2.3. Human LF Cell Isolation and H₂O₂ and NAC Administration. First, the LF specimens were washed with phosphate-buffered saline until all the residual adipose or connective tissues had been fully removed. The specimens were then minced into 0.5 mm³ pieces and placed in a 10 cm culture dish with 10 mL of high-glucose Dulbecco’s modified Eagle’s medium (Gibco, Melbourne, Australia) with 10% fetal bovine serum (Gibco) and 100 U/mL of penicillin. The specimens were incubated at 37°C in an air-humidified incubator containing 5% CO₂, and the culture medium was changed twice weekly. When the LF cells reached an appropriate confluence in the dishes, they were treated with 0.25% trypsin and subcultured in accordance with the aforementioned protocols. After the third passage, the derived cells were used for the experiments. The cells derived from the LSS patients were seen as hypertrophied LF cells, while the ones derived from the LDH patients were regarded as healthy ones. The former was the experimental group, and the latter was the control group. The descriptions came from the previous studies for LFH [4, 37]. Before proceeding to experiments, cell characterization was performed. In the experiments, 25 μM H₂O₂ was selected to induce oxidative stress, as described in other studies [38, 39]. Furthermore, 10 mM NAC was administered as the oxidative...
scavenger and antioxidant precursor for ROS suppression; the NAC concentration was also based on the suggestions of other cell-related studies [38, 40–43].

2.4. Quantification of ROS Activity in Hypertrophic LF Cells. The ROS levels were measured using 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA), a fluorescent dye that can detect H$_2$O$_2$, hydroxyl and peroxyl radicals, peroxynitrite anions, and other ROS activities in cells. The LF cells isolated from the LSS specimens were placed in a 6 cm dish and divided into three groups: the first group comprised cells without treatment (control group), the second group comprised cells subjected to 30 min or 24 h of 25 μM H$_2$O$_2$ treatment (H$_2$O$_2$ treatment group), and the third group comprised cells subjected to 30 min of pretreatment with 10 mM NAC and then stimulation with H$_2$O$_2$ (NAC pretreatment–H$_2$O$_2$ stimulation group). All cells were stained with 25 μM of DCFH-DA (ab113851, DCFDA cellular ROS detection assay kit) for 30 min at 37°C, and the ROS levels were measured after stimulation with H$_2$O$_2$, with or without NAC suppression, by using a fluorescence microplate reader (Ex/Em = 485/535 nm). Laboratory data were analyzed using an unpaired t-test.

2.5. Western Blot Analysis. After treatment with H$_2$O$_2$ with or without NAC, the tissue was lysed in ice-cold lysis buffer (1:10; w/v) containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.2), 10% glycerol, 1% Triton X-100, 10 μg/mL of leupeptin, 10 μg/mL of aprotinin, and 1 mM phenylmethylsulfonyl fluoride. The solution was centrifuged at 12,000 rpm for 10 minutes, and the protein concentration was measured using a protein assay dye (Bio-Rad Laboratories, Hercules, CA, USA), with bovine serum albumin as the standard. We added 8% and 10% sodium dodecyl sulfate polyacrylamide gel for electrophoresis and then transferred the samples to nitrocellulose sheets (NEN Life Science Products, Boston, MA, USA) in a transfer apparatus (Bio-Rad) running at 1.2 A for 2 h. After blocking the blots with 5% nonfat skimmed milk in Tween 20, we added primary antibodies against the target proteins (GPX-1, TGF-β, iNOS, β-actin, p38, p-p38, p65, p-p65, α-SMA, collagen I, and vimentin) and then again added anti-rabbit IgG conjugated with.
hypertrophied LF cells, after 30 minutes or 24 hours of H$_2$O$_2$ treatment, the response to oxidative stress would be checked via quantifying the level of p-p38, p-p65, iNOS, TGF-β (Abcam, ab178945), p38 (GeneTex, GTX110720), phosphorylated p38 (p-p38; Abcam, ab88147), iNOS (Abcam, ab178945), p-p65 (Cell Signaling Technology, 3033), p65 (Cell Signaling Technology, 6956), α-smooth muscle actin (SMA; Abcam, ab7817), anti-β-actin (Thermo Fisher Scientific), anti-GPx-1/2 (SANTA CRUZ, sc-130348), and anti-vimentin (Santa Cruz Biotechnology, sc-6260). The graphical scheme of the study is shown in Figure 3.

Table 1: Patient characteristics.

|                | LDH       | LSS       | p value*  |
|----------------|-----------|-----------|-----------|
| Number         | 24        | 28        | <0.005    |
| Sex (male/female) | 17/7     | 8/20      | <0.001    |
| Age (years)    | 43.1 ± 17.8 | 67.8 ± 9.2 | <0.001    |
| BMI (kg/m$^2$) | 26.2 ± 8.3 | 25.5 ± 4.3 | 0.707     |
| DM             | 7/24      | 4/28      | 0.19      |
| HTN            | 6/24      | 12/28     | 0.177     |
| Respiratory disease | 1/24 | 1/28 | 0.911 |
| Smoking        | 6/24      | 3/28      | 0.175     |
| LF thickness (mm) | 2.7 ± 0.4 | 5.1 ± 0.7 | <0.001    |

*p value generated using a chi-square test or independent t-test; respiratory diseases including asthma and bronchiectasis; LDD: lumbar disc herniation; LSS: lumbar spinal stenosis; BMI: body mass index; DM: diabetes mellitus; HTN: hypertension.

alkaline phosphatase (dilution 1:5000; Jackson Immuno Research Laboratories, Philadelphia, PA, USA). Immunoblots were developed using 5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium solution (Kirkegaard and Perry Laboratories, Baltimore, MD, USA). The proteins were quantified through densitometry using the Image] computer program (National Institutes of Health; available at http://rsb.info.nih.gov/ij/). The following antibodies were used in this study: collagen I (Abcam, ab88147), iNOS (Abcam, ab178945), p38 (GeneFex, GTX110720), phosphorylated p38 (p-p38; Abcam, ab195049), p-p65 (Cell Signaling Technology, 3033), p65 (Cell Signaling Technology, 6956), α-smooth muscle actin (SMA; Abcam, ab7817), anti-β-actin (Thermo Fisher Scientific), anti-GPx-1/2 (SANTA CRUZ, sc-133160), anti-TGF-β (Santa Cruz Biotechnology, sc-130348), and anti-vimentin (Santa Cruz Biotechnology, sc-6260).

2.6. Statistical Analysis. Data on the patients’ characteristics are presented as the mean ± standard deviation. An independent t-test and a chi-square test were used to compare the LDH and LSS groups. A one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test, was used to analyze data regarding cell cultures harvested at different time points. All data in this study were analyzed using SPSS (version 17; SPSS, Chicago, IL, USA).

3. Results

3.1. LSS Patients Were Older and Had More Hypertrophic LF Tissues Than Did LDH Patients. We included 52 patients in this study, of whom 28 were in the LSS group (undergoing decompression surgery for lumbar spinal stenosis) and the remaining were in the lumbar disc herniation (LDH) group. The mean ages of the patients in the LSS and LDH groups were 67.8 ± 9.2 and 43.1 ± 17.8 years, respectively (Table 1); therefore, the patients in the LSS group were significantly older than those in the LDH group (p < 0.001). In addition, the mean LF thickness in the LSS group was significantly higher than that in the LDH group (5.1 ± 0.7 vs. 2.7 ± 0.4 mm; p < 0.001). In terms of sex, the LSS group exhibited a significantly higher female predominance than did the LDH group. The two groups did not differ significantly in terms of body mass index (p = 0.707), diabetes mellitus (p = 0.19), hypertension (p = 0.177), respiratory disease (p = 0.911), or smoking incidence (p = 0.175). LF thickness was weakly associated with age and sex, consistent with the report of a previous study [44]. In summary, the patient population included in this
study was considered to be a representative sample because of the compatibility of its characteristics with those reported by previous epidemiologic studies [3, 45].

3.2. Intracellular Signaling and Inflammation Were More Active in Hypertrophic LF Cells. After the cells were subcultured until the third passage, hypertrophic and healthy LF cells were exposed to H2O2 treatment for 30 min to stimulate oxidative stress. Before oxidative stress stimulation, the background levels of p38 MAPK signaling and iNOS were significantly higher in the hypertrophic LF cells than in the healthy cells, indicating that the hypertrophic LF cells had proinflammatory properties and more active intracellular signaling. After H2O2 treatment, the p-p38 and iNOS levels in the hypertrophic LF cells exhibited a more evident increase than did those in the healthy LF cells. In the healthy LF cells, the p-p38 levels increased significantly but the iNOS levels did not. Notably, the α-SMA levels did not increase after 30 min of H2O2 treatment in either group (Figure 4). This finding is consistent with that of another study [46].

3.3. Increased Oxidative Stress Capacities and Decreased Antioxidant Markers Were Present in Hypertrophic LF Cells after H2O2 Treatment, Which Was Reversed through Antioxidant (NAC) Administration. Under H2O2-induced oxidative stress, the levels of ROS production were significantly elevated and the expression of GPX-1/2, a key intracellular antioxidant, was significantly inhibited in the H2O2 treatment group compared with the control group. In the NAC pretreatment-H2O2 stimulation group, ROS production decreased and GPX-1/2 levels increased. This indicates that NAC functions as an oxidative scavenger and antioxidant replenisher in hypertrophic LF cells, countering H2O2-induced oxidative stress (Figure 5). These results suggest that the proinflammatory and fibrogenic effects of oxidative stress in hypertrophic LF cells could be partially reversed by antioxidants.

3.4. Administration of NAC Reversed the Proinflammatory and Fibrogenic Effects of Oxidative Stress in Hypertrophic LF Cells. Under H2O2-induced oxidative stress, the hypertrophic LF cells exhibited significantly elevated levels of inflammatory cytokines (including iNOS and TGF-β), expression of activated intracellular signaling pathways (including p-p38 and p-p65), and levels of fibrotic markers (including collagen I and vimentin). The expression level of α-SMA also showed a trend of elevation with H2O2 treatment. NAC administration led to a decrease in oxidative stress-induced inflammation, intracellular signaling, and fibrosis (Figure 6). These results are consistent with those of another study that reported a positive association between LFH and oxidative stress-induced inflammation, intracellular signaling, and fibrosis [17]. Additionally, the results suggest that the proinflammatory and fibrogenic effects of oxidative stress in hypertrophic LF cells could be partially reversed by antioxidants.

4. Discussion

This study revealed that intracellular signaling activities and inflammatory markers in hypertrophic LF cells were consistently higher than those in healthy LF cells. These hypertrophic LF cells exhibited a more marked response against oxidative stress than did the healthy cells. Under H2O2-induced oxidative stress, the increase in ROS production along with the decrease in reducing substances
induced the activation of intracellular signaling and the expression of inflammatory and fibrotic markers; these findings are consistent with the results of another study [17]. NAC administration effectively suppressed oxidative stress markers, replenished antioxidant capacity, and curbed the expression of proinflammatory and fibrogenic mediators. Moreover, NAC promoted detoxification, which may be related to the stimulation of GSH biosynthesis. Overall, oxidative stress engendered an increase in the expression of intracellular signaling pathways and inflammatory and fibrotic markers associated with the development of LFH, and this increase was countered by the administration of the antioxidant agent, NAC (Figure 7). These results indicate that NAC has potential as a novel therapy for LFH.

Oxidative stress imbalance is considered a factor in the development of several diseases, including Alzheimer’s disease, PD, fibrosing alveolitis, acute lung injury, liver disease, and vascular disease [47–49]. Therefore, studies have explored the potential clinical application of antioxidants such as NAC; vitamins A, C, and E; folic acid; curcumin; and pyrrolidinium dithiocarbamate [18, 20, 28, 29, 50, 51]. Regarding PD, studies have reported that decreased nigral GSH levels were strongly associated with disease progression and that intravenous and oral NAC administration engendered a significant increase in serum GSH levels and significant improvements in clinical symptoms [20, 52]. Regarding fibrosing alveolitis, a study noted inappropriate oxidative stress and reduced antioxidant marker expression due to overactive phagocytes; nevertheless, oral NAC administration led to the recovery of antioxidant markers and improvements in pulmonary function [28]. Regarding acute lung injury, intravenous NAC administration led to improvements in oxygenation through the replenishment of reducing substances [24]. A study demonstrated higher ROS levels and lower antioxidant capacity levels (GSH) in hypertrophic LF cells; the study also noted that oxidative stress was correlated with inflammation and fibrosis [53]. Other studies have confirmed that NAC could replenish GSH biosynthesis without the blockage
Figure 6: Continued.
of negative feedback from buthionine sulfoximine [46, 54, 55]. Our study revealed similar results. Specifically, we observed that NAC partially blocked H2O2-induced ROS production and replenished depleted GPX-1/2, a reducing substance. In addition, NAC inhibited oxidative stress-induced inflammation, intracellular signaling, and fibrosis. These results indicate that NAC can protect LF cells against acute oxidative insult. Our study is the first to explore the use of an antioxidant as a treatment for LFH. The study expands the applications of NAC in oxidative stress-related diseases, including LFH. Long-term intake of NAC might ameliorate the depletion of reducing substances in hypertrophic LF cells, such as in PD [20]. However, the potential preventive effects of NAC against LFH should be further explored. Since 2021, the U.S. Food and Drug Administration has been considering NAC as a legal dietary supplement because it has few side effects and potential health benefits. If this proposal is adopted, the long-term intake of NAC as an antioxidant supplement, similar to vitamins, will be possible.

Studies have reported that elevated inflammatory cytokines such as TGF-β1, IL-6, MMPs, NO, PGE2, and TNF-α stimulate fibrosis, angiogenesis, and intracellular signaling pathways, resulting in LFH progression [4, 9–12, 56, 57]. The p38/MAPK and p65/nuclear factor-κB intracellular signaling pathways are also involved in the development of LFH. TGF-β1 increases collagen, CTGF, IL-1, and IL-6 expression through the p38/MAPK pathway [17, 53, 58–64]. Furthermore, NF-κB p65 activation engendered an increase in IL-6, IL-1, TGF-β, and collagen fiber expression [12, 17, 60, 65]. In addition, myofibroblasts, which are fibroblast phenotypes, constitute a key component of LFH. Myofibroblasts can be differentiated from fibroblasts and protomyofibroblasts on the basis of the stimulation of mechanical stress and TGF-β1. Specifically, myofibroblasts generate a stronger contractile force, increase the synthesis of extracellular matrix components such as collagen, and elevate fibrosis-related cytokine expression, which can exacerbate fibrocontractive diseases [66]. Myofibroblast dysregulation results in the progression of fibrosis-related diseases [61]. Studies have reported that in hypertrophic LF cells, especially in the dorsal layer, myofibroblast activity was elevated and that α-SMA (a myofibroblast marker) expression was increased and was strongly correlated with increased type 1 collagen expression; moreover, α-SMA expression was further increased under hypoxic stimulation [6, 67]. In our study, in hypertrophied LF cells, elevated protein expression levels of p-p38 and p-p65 were detected after a 30 min H2O2 treatment and the expression levels of iNOS, TGF-β, vimentin, and collagen I were elevated after 24 h H2O2 treatment; this phenomenon is similar to the pathological molecular mechanism of LFH reported in other studies. NAC administration resulted in the regression of fibrotic markers under H2O2 treatment with or without NAC. Under 25 mM H2O2-induced oxidative stress for 30 min, significantly elevated protein expression levels of p-p38 and p-p65 were detected, and under 25 mM H2O2-induced oxidative stress for 24 h, significantly elevated protein expression levels of iNOS, TGF-β, vimentin, and collagen I were also detected. After a 30 min pretreatment with 10 mM NAC, these markers were all significantly suppressed, except for iNOS and TGF-β. In spite of statistical non-significance, iNOS and TGF-β also showed a trend of diminish with NAC administration. (n = 5; *p < 0.05 compared with the control group or H2O2 stimulated group; **p < 0.01 compared with the control group or H2O2 stimulated group; ***p < 0.001 compared with the control group or H2O2 stimulated group; values were derived from a one-way ANOVA and Tukey’s post hoc test).

Changes in cell phenotypes, including the distinct fibroblast phenotypes involved in hypertrophic scar formation, play a role in the development of several diseases [68]. The dysregulation of fibroblasts, myofibroblasts, and macrophages plays a major role in the development of LFH [57]. However, no other studies have considered the diverse phenotypes of LF cells. This study is the first to reveal differences between hypertrophic and healthy LF cells. Specifically, we demonstrated that the hypertrophic LF cells exhibited significantly higher background levels of p38/MAPK signaling and iNOS than did the healthy
LF cells. Under oxidative stress, p-p38 and iNOS levels increased more markedly in the hypertrophic LF cells than in the healthy cells, indicating the proinflammatory properties of and highly active intracellular signaling in the hypertrophic cells. This finding suggests that the pathological phenotype of hypertrophic LF cells is different from that of healthy cells. In summary, the pathological status of hypertrophic LF cells is different from that of healthy cells, resulting in an increase in intracellular signaling and inflammatory reactions in such cells under oxidative stress. The increase in baseline endogenous oxidative capacity in hypertrophic LF cells along with the vulnerability of such cells to oxidative stress creates a vicious cycle that may result in the rapid exacerbation of LFH.

Our study has some limitations. First, the age of the LSS and LDH patients was not matched perfectly. Secondly, the study was confined to experiments on cells. Although NAC was verified to have a protective effect against LFH, its low oral bioavailability (4%–10%) and high first-pass effect could engender challenges in its clinical application. Until now, no animal models or clinical trials have applied NAC for LFH treatment. Accordingly, additional clinical studies should be performed to validate the clinical efficacy, therapeutic dosage, and administration route of NAC for LFH. Thirdly, the current study did not cover analyses of posttranscriptional modifications and the secretome associated with LFH. The qPCR of inflammatory markers and ELISA/luminex analyses of inflammatory markers secreted by cultured cells would be performed in the future studies.

5. Conclusions
This study revealed that oxidative stress damaged both hypertrophic and healthy LF cells, with the hypertrophic LF cells exhibiting a more active inflammatory response and p38 MAPK pathway than did the healthy cells. This indicates that the pathological phenotype of hypertrophic LF cells has proinflammatory properties. Under oxidative stress, the hypertrophic LF cells exhibited increased expression levels of fibrotic and inflammatory markers and intracellular signaling, and NAC administration reversed the proinflammatory and fibrogenic effects of oxidative stress. These results suggest that antioxidants could form the basis of a novel preventive or therapeutic pharmacologic treatment for LFH. In the future, N-acetylcysteine might be long-term administered as a treatment for LFH based on few side effects and antioxidative property. However, there were some limitations of the study such as the distinct population between LDH and LSS groups and the absence of clinical trial applying NAC for LFH treatment.

Data Availability
The data presented in this study are available on request from the corresponding author.

Ethical Approval
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of National Cheng Kung University Hospital (A-ER-108-541, A-ER-110-001).

Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions

CLL, YCH, and HCC are assigned to the conceptualization. SSS, YFL, and HCC are assigned to the methodology. KLT, TYT, CHK, and YJS did the validation. HCC did formal analysis. YCH and HCC did the investigation. YCH and HCC curated the data. YCH and HCC are responsible for the writing—original draft preparation. YCH and HCC are responsible for the writing—review and editing. YCH and HCC are assigned to the visualization. KLT, TYT, CHK, and YJS did the supervision. KLT, TYT, CHK, and YJS are responsible for the project administration. CLL acquired funding. All authors have read and agreed to the published version of the manuscript. Yu-Chia Hsu and Hao-Chun Chuang contributed equally to this work.

Acknowledgments

This study was supported by grants funded by the Ministry of Science and Technology, Taiwan (MOST 107-2221-E-006-068, MOST 109-2314-B-006-020, and MOST 110-2314-B-006-020, and MOST 109-2314-B-006-027-MY3) to C.L.L. We thank the National Cheng Kung University Hospital, Taiwan (NCKUH-11102054) to C.L.L. This study was also supported by National Cheng Kung University Hospital, Taiwan (NCKUH-11102054) to C.L.L. We thank the Wallace Academic Editing for the edition of this manuscript.

References

[1] B. Sachs and J. Fraenkel, “Progressive ankylosis rigidity of the spine (spondylose rhizomélique),” The Journal of Nervous and Mental Disease, vol. 27, no. 1, pp. 1–15, 1900.

[2] K. Watanabe, M. Sekiguchi, K. Yonemoto et al., "Bowel/bladder dysfunction and numbness in the sole of the both feet in lumbar spinal stenosis - a multicenter cross-sectional study," Journal of Orthopaedic Science, vol. 22, no. 4, pp. 647–651, 2017.

[3] L. Kalichman, R. Cole, D. H. Kim et al., “Spinal stenosis prevalence and association with symptoms: the Framingham study,” The Spine Journal, vol. 9, no. 7, pp. 545–550, 2009.

[4] J. B. Park, J. K. Lee, S. J. Park, and K. D. Riew, “Hypertrophy of ligamentum flavum in lumbar spinal stenosis associated with increased protease inhibitor concentration,” The Journal of Bone and Joint Surgery, vol. 87, no. 12, pp. 2750–2757, 2005.

[5] M. Djurasovic, S. D. Glassman, L. Y. Carreon, and J. R. Dimar II, “Contemporary management of symptomatic lumbar spinal stenosis,” The Orthopedic Clinics of North America, vol. 41, no. 2, pp. 183–191, 2010.

[6] J. W. Hur, T. Bae, S. Ye et al., “Myofibroblast in the ligamentum flavum hypertrophic activity,” European Spine Journal, vol. 26, no. 8, pp. 2021–2030, 2017.

[7] J. Jezek, J. Sepitka, M. Daniel et al., “The role of vascularization changes in ligamentum flavum mechanical properties and development of hypertrophy in patients with lumbar spinal stenosis,” The Spine Journal, vol. 20, no. 7, pp. 1125–1133, 2020.

[8] H. Kosaka, K. Sairyo, A. Biyani et al., “Pathomechanism of loss of elasticity and hypertrophy of lumbar ligamentum flavum in elderly patients with lumbar spinal canal stenosis,” Spine, vol. 32, no. 25, pp. 2805–2811, 2007.

[9] S. Lakemeier, M. D. Schofer, L. Foltz et al., “Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor, and matrix metalloproteinases 1, 3, and 9 in hypertrophied ligamentum flavum,” Journal of Spinal Disorders & Techniques, vol. 26, no. 7, pp. 400–406, 2013.

[10] M. Lühr, J. A. Hampel, J. Y. Lee, R. I. Ernestus, M. Deckert, and W. Stenzel, “Hypertrophy of the lumbar ligamentum flavum is associated with inflammation-related TGF-β expression,” Acta Neurochirurgica, vol. 153, no. 1, pp. 134–141, 2011.

[11] H. J. Moon, Y. K. Park, Y. Ryu et al., “The angiogenic capacity from ligamentum flavum subsequent to inflammation: a critical component of the pathomechanism of hypertrophy,” Spine, vol. 37, no. 3, pp. E147–E155, 2012.

[12] T. Nakamura, T. Okada, M. Endo, T. Nakamura, Y. Oike, and H. Mizuta, “Angiopoietin-like protein 2 promotes inflammatory conditions in the ligamentum flavum in the pathogenesis of lumbar spinal canal stenosis by activating interleukin-6 expression,” European Spine Journal, vol. 24, no. 9, pp. 2001–2015, 2015.

[13] X. Qu, Z. Chen, D. Fan, C. Sun, and Y. Zeng, “MiR-132-3p regulates the osteogenic differentiation of thoracic ligamentum flavum cells by inhibiting multiple osteogenesis-related genes,” International Journal of Molecular Sciences, vol. 17, no. 8, p. 1370, 2016.

[14] J. Chen, Z. Liu, G. Zhong et al., “Cyclic stretch enhances apoptosis in human lumbar ligamentum flavum cells via the induction of reactive oxygen species generation,” The Journal of Spinal Cord Medicine, vol. 39, no. 4, pp. 450–454, 2016.

[15] S. Dechsupa, W. Yingsakmongkol, W. Limthongkul, W. Singhanadgige, and S. Hansoawek, “Relative telomere length and oxidative DNA damage in hypertrophic ligamentum flavum of lumbar spinal stenosis,” PeerJ, vol. 6, article e5381, 2018.

[16] Ş. C. Yücsat and T. Çakır, “Decreased catalase expression is associated with ligamentum flavum hypertrophy due to lumbar spinal canal stenosis,” Medicine, vol. 98, no. 15, article e15192, 2019.

[17] H. C. Chuang, K. L. Tsai, K. J. Tsai et al., “Oxidative stress mediates age-related hypertrophy of ligamentum flavum by inducing inflammation, fibrosis, and apoptosis through activating Akt and MAPK pathways,” Aging (Albany NY), vol. 12, no. 23, pp. 24168–24183, 2020.

[18] M. Bas, V. Tugcu, E. Kemahlı et al., “Curcumin prevents shock-wave lithotripsy-induced renal injury through inhibition of nuclear factor kappa-B and inducible nitric oxide synthase activity in rats,” Urological Research, vol. 37, no. 3, pp. 159–164, 2009.

[19] J. F. Chen, H. Liu, H. F. Ni et al., “Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats,” PLoS One, vol. 8, no. 12, article e83593, 2013.

[20] L. D. Coles, P. J. Tuite, G. Öz et al., “Repeated-dose oral N-acetylcysteine in Parkinson’s disease: pharmacokinetics and effect on brain glutathione and oxidative stress,” Journal of Clinical Pharmacology, vol. 58, no. 2, pp. 158–167, 2018.

[21] G. Fang, L. Hong, C. Liu et al., “Oxidative status of cardinal ligament in pelvic organ prolapse,” Experimental and Therapeutic Medicine, vol. 16, no. 4, pp. 3293–3302, 2018.

[22] G. Poli, “Pathogenesis of liver fibrosis: role of oxidative stress,” Molecular Aspects of Medicine, vol. 21, no. 3, pp. 49–98, 2000.
[23] J. Sochman, J. Vrbská, B. Musilová, and M. Roček, “Infarct size limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients,” *Clinical Cardiology*, vol. 19, no. 2, pp. 94–100, 1996.

[24] P. M. Suter, G. Domenighetti, M. D. Schaller, M. C. Lavérière, R. Ritz, and C. Perret, “N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study,” *Chest*, vol. 105, no. 1, pp. 190–194, 1994.

[25] A. Kibl, A. M. Lükinc, V. Dambic, I. Juric, and K. Selthofer-Relict, “Oxidative stress in ischemic heart disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2020, Article ID 6627144, 30 pages, 2020.

[26] A. Scholze, J. Jankowski, J. Pedraza-Chaverrí, and P. Evenepoel, “Oxidative stress in chronic kidney disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 8375186, 2 pages, 2016.

[27] I. Achour, A. M. Arel-Dubeau, J. Renaud et al., “Oleuropein prevents neuronal death, mitigates mitochondrial superoxide production and modulates autophagy in a dopaminergic cellular model,” *International Journal of Molecular Sciences*, vol. 17, no. 8, p. 1293, 2016.

[28] J. Behr, K. Maier, B. Degenkolb, F. Krombach, and C. Vogelmeier, “Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression,” *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 6, pp. 1897–1901, 1997.

[29] A. Eklund, O. Eriksson, L. Håkansson et al., “Oral N-acetylcysteine reduces selected humoral markers of inflammation in subjects using N-acetylcysteine as an antioxidants,” *Clinical Biochemistry and Nutrition*, vol. 443, 2019.

[30] J. Sochman and J. H. Peregrin, “Total recovery of left ventricular function after acute myocardial infarction: comprehensive characterization of cultured human ligamentum flavum cells in lumbar spine stenosis,” *AJNR. American Journal of Neuroradiology*, vol. 31, no. 10, pp. 1813–1816, 2010.

[31] F. H. Chokshi, R. M. Quencer, and W. R. Smoker, “The ‘thickened’ ligamentum flavum: is it buckling or enlargement?,” AJNR. *American Journal of Neuroradiology*, vol. 31, no. 10, pp. 2018–2016, 2010.

[32] C. W. Jiang, W. C. Chen, H. W. Liu, I. C. Wang, and C. H. Chen, “Evaluating osteogenic potential of ligamentum flavum cells cultivated in photore sponsive hydrogel that incorporates bone morphogenetic protein-2 for spinal fusion,” *International Journal of Molecular Sciences*, vol. 16, no. 10, pp. 23318–23336, 2015.

[33] J. Jordan, K. Konstantinou, and J. O’Dowd, “Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease,” *Cell & Bioscience*, vol. 9, no. 1, p. 20, 2019.

[34] H. Okazawa, M. Ikawa, T. Tsujikawa et al., “The thickness of the ligamentum flavum in relation to age and gender,” *Clinical Anatomy*, vol. 23, no. 1, pp. 79–83, 2010.

[35] J. Jordan, K. Konstantinou, and J. O’Dowd, “Herniated lumbar disc,” BMJ Clinical Evidence, vol. 2009, p. 1118, 2009.

[36] P. Parra-Flores, J. A. Riquelme, P. Valenzuela-Bustamante et al., “The absorption of acetic acid, deferoxamine and N-acetylcysteine improves cardiac fibroblast viability and cellular function associated with tissue repair damaged by simulated ischemia/reperfusion,” *Antioxidants (Basel)*, vol. 8, no. 12, pp. 614, 2019.

[37] N. Specchia, A. Pagnotta, A. Gigante, G. Logroscino, and A. Toesca, “Characterization of cultured human ligamentum flavum cells in lumbar spine stenosis,” *Journal of Orthopaedic Research*, vol. 19, no. 2, pp. 294–300, 2001.

[38] J. Liu, L. Wang, J. Cai et al., “N-acetylcysteine alleviates H2O2-induced damage via regulating the redox status of intracellular antioxidants in H9c2 cells,” *International Journal of Molecular Medicine*, vol. 43, no. 1, pp. 199–208, 2019.

[39] R. C. Orihuela-Campos, N. Tamaki, R. Mukai et al., “Biological impacts of resveratrol, quercetin, and N-acetylcysteine on oxidative stress in human gingival fibroblasts,” *Journal of Clinical Biochemistry and Nutrition*, vol. 56, no. 3, pp. 220–227, 2015.

[40] P. Parra-Flores, J. A. Riquelme, P. Valenzuela-Bustamante et al., “The mechanism of action of N-acetylcysteine (NAC): the emerging role of antioxidant and clinical effects,” *Anti oxidants (Basel)*, vol. 8, no. 12, pp. 614, 2019.

[41] X. Li and H. Wang, “Curcumin induces oxidative stress in human gingival fibroblasts,” *International Journal of Molecular Sciences*, vol. 20, 2019.

[42] P. Parra-Flores, J. A. Riquelme, P. Valenzuela-Bustamante et al., “The role of N-acetylcysteine in the pathogenesis of ligamentum flavum hypertrophy,” *Spine Surgery and Related Research*, vol. 20, 2010.

[43] H. Okazawa, M. Ikawa, T. Tsujikawa et al., “Cerebral oxidative stress in early Alzheimer’s disease evaluated by 64Cu-ATSM PET/MRI: a preliminary study,” *Antioxidants*, vol. 11, no. 5, pp. 1022, 2022.

[44] H. Cao, D. Yu, X. Yan et al., “Hypoxia destroys the microstructure of microtubules and causes dysfunction of endothelial cells via the PI3K/Stathmin1 pathway,” *Cell & Bioscience*, vol. 9, no. 1, p. 20, 2019.

[45] X. Li and H. Wang, “Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease,” *Cell & Bioscience*, vol. 10, no. 1, p. 140, 2020.

[46] P. Kumar, O. Osahon, D. B. Vides, N. Hanania, C. G. Minard, and R. V. Sekhar, “Severe glutathione deficiency, oxidative stress and oxidant damage in adults hospitalized with COVID-19: implications for GlyNAC (glucose and N-acetylcysteine) supplementation,” *Antioxidants*, vol. 11, no. 1, p. 50, 2022.

[47] R. V. Sekhar, “GlyNAC (glucose and N-acetylcysteine) supplementation improves impaired mitochondrial fuel oxidation and lowers insulin resistance in patients with type 2 diabetes:...
results of a pilot study,” Antioxidants (Basel), vol. 11, no. 1, p. 154, 2022.

[52] D. A. Monti, G. Zabrecky, D. Kremens et al., “N-acetyl cysteine is associated with dopaminergic improvement in Parkinson’s disease,” Clinical Pharmacology and Therapeutics, vol. 106, no. 4, pp. 884–890, 2019.

[53] Z. M. Zhong, J. T. Chen, Y. Zhang et al., “Growth/differentiation factor-5 induces osteogenic differentiation of human ligamentum flavum cells through activation of ERK1/2 and p38 MAPK,” Cellular Physiology and Biochemistry, vol. 26, no. 2, pp. 179–186, 2010.

[54] V. Paschalis, A. A. Theodorou, N. V. Margaritelis, A. Kyparos, and M. G. Nikolaidis, “N-acetylcysteine supplementation increases exercise performance and reduces oxidative stress only in individuals with low levels of glutathione,” Free Radical Biology & Medicine, vol. 115, pp. 288–297, 2018.

[55] P. G. Richman and A. Meister, “Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione,” The Journal of Biological Chemistry, vol. 250, no. 4, pp. 1422–1426, 1975.

[56] Y. Cao, Y. Zhan, S. Qiu et al., “Integrative analysis of genome-wide DNA methylation and single-nucleotide polymorphism identified ACSM5 as a suppressor of lumbar ligamentum flavum hypertrophy,” Arthritis Research & Therapy, vol. 23, no. 1, p. 251, 2021.

[57] C. Sun, H. Zhang, X. Wang, and X. Liu, “Ligamentum flavum fibrosis and hypertrophy: molecular pathways, cellular mechanisms, and future directions,” The FASEB Journal, vol. 34, no. 8, pp. 9854–9868, 2020.

[58] Y. L. Cao, Y. Duan, L. X. Zhu, Y. N. Zhan, S. X. Min, and A. M. Jin, “TGF-β1, in association with the increased expression of connective tissue growth factor, induce the hypertrophy of the ligamentum flavum through the p38 MAPK pathway,” International Journal of Molecular Medicine, vol. 38, no. 2, pp. 391–398, 2016.

[59] Y. H. Chao, Y. H. Tsuang, J. S. Sun, M. G. Sun, and M. H. Chen, “Centrifugal force induces human ligamentum flavum fibroblasts inflammation through activation of JNK and p38 pathways,” Connective Tissue Research, vol. 53, no. 5, pp. 422–429, 2012.

[60] Y. H. Chao, H. S. Yang, M. G. Sun, J. S. Sun, and M. H. Chen, “Elastin-derived peptides induce inflammatory responses through the activation of NF-κB in human ligamentum flavum cells,” Connective Tissue Research, vol. 53, no. 5, pp. 407–414, 2012.

[61] D. Fan, Z. Chen, D. Wang, Z. Guo, Q. Qiang, and Y. Shang, “Osterix is a key target for mechanical signals in human thoracic ligamentum flavum cells,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 577–584, 2007.

[62] C. Lu, Z. Liu, H. Zhang, Y. Duan, and Y. Cao, “Mechanism of p38 mitogen activated protein kinase signaling pathway on promoting the hypertrophy of human lumbar ligamentum flavum via transforming growth factor β 1/connective tissue growth factor,” Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi= Zhongguo Xiu Fu Chongjian Waike Zazhi= Chinese Journal of Reparative and Reconstructive Surgery, vol. 33, no. 6, pp. 730–735, 2019.

[63] Y. Shunzhi, L. Zhonghai, and Y. Ning, “Mechanical stress affects the osteogenic differentiation of human ligamentum flavum cells via BMP-Smad1 signaling pathway,” Molecular Medicine Reports, vol. 16, no. 5, pp. 7692–7698, 2017.

[64] K. Yagi, Y. Goto, K. Kato et al., “p38 mitogen-activated protein kinase is involved in Interleukin-6 secretion from human ligamentum flavum-derived cells stimulated by tumor necrosis factor-α,” Asian Spine Journal, vol. 15, no. 6, pp. 713–720, 2021.

[65] C. Sun, Z. Wang, J. W. Tian, and Y. H. Wang, “Leptin-induced inflammation by activating IL-6 expression contributes to the fibrosis and hypertrophy of ligamentum flavum in lumbar spinal canal stenosis,” Bioscience Reports, vol. 38, no. 2, 2018.

[66] G. Gabbiani, “The myofibroblast in wound healing and fibrocontractive diseases,” The Journal of Pathology, vol. 200, no. 4, pp. 500–503, 2003.

[67] F. Hayashi, M. Morimoto, K. Higashino et al., “Myofibroblasts are increased in the dorsal layer of the hypertrophic ligamentum flavum in lumbar spinal canal stenosis,” The Spine Journal, vol. 22, no. 4, pp. 697–704, 2022.

[68] C. C. Chipev and M. Simon, “Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFβ1,” BMC Dermatology, vol. 2, no. 1, p. 13, 2002.